GlassScriptPhysician profile
Mahmoud Mustafa
NPI 1437118197
$36,935.45
in general payments reported to CMS, 2019-2025
54 companies · $2,747 in 2025
The $2,747 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $2,069 · 2021: $3,915 · 2022: $2,622 · 2023: $2,917 · 2024: $3,199 · 2025: $2,747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,819 · Education: $44.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,819.14 |
| Education | $44.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $18,554.91 | 2019-2025 | Biktarvy, Descovy |
| Viiv Healthcare Company | $4,828.20 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Theratechnologies INC. | $3,071.86 | 2019-2025 | Trogarzo, Egrifta |
| Biohaven Pharmaceuticals, INC. | $1,339.43 | 2021 | |
| Pfizer INC. | $1,113.81 | 2019-2025 | |
| Abbvie INC. | $972.50 | 2019-2025 | |
| Janssen Biotech, INC. | $880.89 | 2019-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $756.35 | 2019-2025 | Pifeltro, Delstrigo, Gardasil 9 |
| Napo Pharmaceuticals INC | $723.33 | 2019-2025 | Mytesi |
| Takeda Pharmaceuticals U.S.A., INC. | $560.61 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $378.43 | 2020-2025 | Rexulti |
| Lundbeck LLC | $335.87 | 2020-2025 | Rexulti |
| Novo Nordisk INC | $323.32 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $291.89 | 2019-2023 | Xifaxan |
| Lilly USA, LLC | $288.66 | 2020-2025 | Mounjaro, Zepbound, Emgality |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahmoud Mustafa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.